Opinion|Videos|January 10, 2025
Addressing Social Determinants of Health in Hidradenitis Suppurativa Care
Author(s)Hadar Lev-Tov, MD
Panelist discusses how social determinants of health create significant diagnostic barriers for hidradenitis suppurativa through systemic inequities, limited health care access, and provider knowledge gaps. Health systems can mitigate these challenges through targeted educational, technological, and culturally responsive interventions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do social determinants of health create barriers to timely and accurate diagnosis of HS?
- What strategies can health systems implement to mitigate these barriers?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
4
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
5